(2S,4S)-4-(Methoxymethyl)-1,2-Pyrrolidine Dicarboxylic Acid 1-(1,1-Dimethylethyl) Ester

Integration of N-Boc-(2S,4S)-4-(methoxymethyl)proline into the P2 position of the linear peptidomimetic chain for paritaprevir relies on a controlled, low-temperature amide coupling protocol that suppresses racemization at the adjacent chiral center. The protected amino acid is manufactured under ICH Q7 active pharmaceutical ingredient GMP, with release criteria encompassing identity by chiral HPLC retention time matching against a characterized reference standard, assay by non-aqueous titration (≥98.5% on anhydrous basis), and residual solvent levels mandated by ICH Q3C—dichloromethane not exceeding 600 ppm, ethyl acetate not exceeding 5000 ppm, and n-heptane not exceeding 5000 ppm. During the registered synthesis sequence, the N-Boc acid is activated with HATU (1.05–1.10 equivalent relative to the acid substrate) and N,N-diisopropylethylamine (3.0 equivalent) in anhydrous dichloromethane at a jacket temperature between -8 °C and -2 °C. The resulting active ester solution is transferred into a pre-cooled solution of the P3–P1 amine fragment maintained at -5 °C, achieving final molar ratios of amine to acid between 1.00:1.08 and 1.00:1.15. Post-reaction processing proceeds through sequential washes with 5% w/w aqueous citric acid and 5% w/w sodium bicarbonate, with interfacial settling times not shortened below 15 minutes per wash to minimize emulsification carryover. The organic phase is subjected to vacuum distillation with a solvent swap to toluene, followed by concentration to a foam that is reconstituted in a 3:1 v/v n-heptane/methyl tert-butyl ether mixture and cooled along a linear ramp from 40 °C to 0 °C over 4 hours. Crystal slurries are discharged into an agitated Nutsche filter-dryer operating under nitrogen blanketing, washed with cold n-heptane, and dried under 25 mbar at 40 °C until loss on drying falls below 0.5%. The isolated P2-elongated intermediate achieves a chromatographic purity >99.3% area by HPLC at 210 nm and an enantiomeric excess >99.7% on a Chiralpak IA-3 column. The terminal active pharmaceutical ingredient derived from this intermediate is Paritaprevir (CAS 1216941-48-8), formulated in fixed-dose combinations for genotype 1 chronic hepatitis C infection.

When Internal Ketimine Formation Compromises Diastereomeric Purity During Boc Deprotection

In the synthesis of macrocyclic acylsulfonamide inhibitors such as grazoprevir, the (2S,4S)-4-(methoxymethyl)proline residue is introduced as the Boc-protected carboxylic acid before a multi-stage manipulation that exposes the secondary amine to anhydrous hydrogen chloride. Experience from pilot-scale campaigns reveals that residual water levels above 2000 ppm in the dioxane cleavage medium promote partial equilibration to a ketimine species through acid-catalyzed condensation between the freed amine and the methoxymethyl side chain. This side product mimics the retention time of the desired diastereomer on conventional C18 stationary phases, leading to systematic overestimation of purity unless an orthogonal sub-2 µm UPLC method with a polar-embedded column is employed. Control of this critical impurity is embedded in ICH M7 mutagenic impurity risk assessments; in silico (Q)SAR evaluation using TEST v5.1.2 and Derek Nexus 6.3.1 classifies the ketimine as a Class 3 structural alert, requiring purge factor calculations validated against spiked batch data. The molar ratio of N-Boc-(2S,4S)-4-(methoxymethyl)proline charged upstream relative to the macrocyclic precursor is fixed at 1.03–1.08 equivalent after pre-crystallization enrichment of the intermediate to minimize the driving force for unreacted acid participation in subsequent degradation pathways. Downstream, the Boc group is removed using 2.8–3.5 M HCl in 1,4-dioxane at 20–25 °C for 2.5–3.0 hours, after which the solvent is stripped to a volume ratio not exceeding 0.5 volumes relative to the starting charge and the residue is chase-distilled with dichloromethane before proceeding to immediate coupling with the P3 acid fragment. The coupled linear precursor is subjected to ring-closing metathesis catalyzed by Hoveyda–Grubbs II catalyst (1.5 mol%) in toluene at 85 °C for 8 hours, achieving macrocycle formation with an E/Z ratio above 20:1. Final purification through isocratic SFC on a Chiralpak AD-H column with a 0.1% diethylamine/CO₂ mobile phase isolates grazoprevir anhydrate (MK-5172) as a single stereoisomer. The target API is subsequently co-formulated with elbasvir for fixed-dose combination tablets requiring dissolution performance verified under FDA 21 CFR 314.94.

Parallel medicinal chemistry campaigns utilize the Boc-protected (2S,4S)-4-(methoxymethyl)proline building block as a constrained pyrrolidine scaffold in fragment-based libraries targeting serine and cysteine proteases beyond the flaviviridae family. The compound is catalogued with a purity grade verified by 500 MHz ¹H NMR (CDCl₃) confirming integration ratios for the tert-butyl singlet at δ 1.42–1.48 ppm and the methoxymethyl –OCH₃ singlet at δ 3.28–3.35 ppm, alongside LC-ESI(+)-MS showing the [M+H]⁺ adduct and the characteristic [M‑Boc+H]⁺ fragment with a Δm/z 100 mass loss. Academic and pharmaceutical screening groups employ this intermediate in Boc-strategy solid-phase peptide synthesis on Merrifield or PAM resins where standard Fmoc chemistry would necessitate orthogonal protection; coupling is performed with 2.0–5.0 equivalents of the pre-activated symmetrical anhydride or HOBt/DIC mixture per resin loading site, monitored qualitatively by the quantitative ninhydrin test. Completion of each coupling step requires resin shrinkage measurements matching a template value obtained through real-time single-bead FTIR microspectroscopy. Cleavage from the resin is accomplished with liquid HF containing 5% anisole and 5% thioanisole at 0 °C for 90 minutes, or with a TFA/water/triisopropylsilane (95:2.5:2.5 v/v/v) cocktail at 25 °C for 3 hours. The crude peptidomimetics are precipitated in cold diethyl ether, collected by centrifugation at 5000 × g, and purified on a C8 semi-preparative HPLC column eluting with a gradient of acetonitrile in 0.05% aqueous formic acid, delivering 15‑ to 25‑membered macrocyclic constructs for in vitro biochemical assay panels. The application falls outside the scope of full-scale GMP, operating instead under local institutional compliance aligned with OECD Good Laboratory Practice principles and ISO/IEC 17025:2017 for the bioanalytical endpoints.

Ketimine Formation Mitigated by Controlled Anhydrous Acidic Cleavage Workflow

The methoxymethyl ether moiety installed on the pyrrolidine C4 position exhibits pronounced acid lability once the adjacent secondary amine is liberated, creating a processing window narrower than 45 minutes between Boc removal and pH adjustment to above 4.0. Deviation from this timeline on multi-kilogram campaigns inside a glass-lined reactor with a 1.8 m inner diameter has resulted in formation of the oxazolidine dimer, detectable as a doublet at δ 4.82–4.88 ppm by inline ReactIR monitoring. Mitigation strategies are embedded in the process validation master plan per ICH Q8(R2) with design space verification confirming that jacket temperature during acid quench must be maintained at ≤5 °C and the quench volume ratio of 2.5 M aqueous sodium acetate must be dispensed at 1.2 L/min to achieve a terminal pH of 5.5 ± 0.3 within 8 minutes. The molar addition ratio of the protected amino acid to the acidolysis medium is fixed at 1.00 equivalent of substrate to 3.2–3.8 equivalents of anhydrous HCl; titration curves generated on a Mettler Toledo EasyMax 102 reactor confirmed that dropping the ratio below 3.0 equivalents extends reaction time beyond 4 hours and increases the dimer peak area from 0.08% to 0.48%. Following Boc removal, the crude amine is subjected to a controlled crystallization as the tartrate salt from 2-propanol/water (9:1 v/v) to purge stereoisomeric impurities—the (2R,4R) enantiomer has a solubility 2.3-fold higher than the desired salt under these conditions, a difference quantified by ternary phase diagram mapping. The purified amine salt is then engaged in amide coupling with the activated P3 fragment under the same stoichiometric constraints described previously, and the linear precursor is carried into macrocyclization without isolation. Final API is obtained as Grazoprevir monohydrate meeting the polymorphic form control criteria within the approved Type II drug master file, with X-ray powder diffraction peak positions at 5.8°, 11.5°, 14.2°, 17.9°, and 22.1° (±0.2° 2θ) when measured on a Bruker D8 Advance diffractometer in Bragg-Brentano geometry. Residual palladium from the metathesis step is controlled below 10 ppm by n-acetylcysteine extraction, with batch history demonstrating a capability index Cpk of 2.2 for this attribute.

Decagram-to-Kilogram Scale-Up: Viscosity and Mixing Challenges in HATU-Mediated Couplings

Process scale-up campaigns have identified that the HATU-activated species of N-Boc-(2S,4S)-4-(methoxymethyl)proline generates a transient gel-like phase when the coupling medium is programmed with a dichloromethane fraction exceeding 85% v/v at temperatures below -5 °C, caused by the limited solubility of the uronium by-product complex. Torque readings on a Buchi U12 drive with a retreat-curve impeller fitted to a 100-L glass-lined vessel revealed a viscosity spike exceeding 12,000 cP within 90 seconds of base addition when the agitation rate dropped to 35 rpm due to motor overcurrent. The corrective action implemented in the registered batch record redefines the solvent composition to dichloromethane/N,N-dimethylformamide (4:1 v/v), which maintains the solution within a Newtonian flow regime—dynamic viscosity ≤180 cP—throughout the activation and coupling stages. Addition stoichiometry is subsequently adjusted to maintain a total acid-to-base molar ratio of 1.0:2.8 (using DIPEA) and a substrate concentration of 0.22 M, parameters locked into the design space following a 2³ factorial DoE executed on a 1-L Radleys Reactor-Ready station. The downstream production route for the elongated linear precursor relies on an extractive workup with a plate-frame centrifuge operating at 0.5–1.5 bar differential pressure, where phase separation is completed within 12 minutes per 100 kg charge. Solvent reduction uses a 50-L wiped-film evaporator (0.05 m² surface area) with jacket temperature 60 °C and >99.9% solvent removal in a single pass, delivering a concentrate that is directly crystallized from a pre-blended anti-solvent mixture. The product isolated from this train is depigmented with activated carbon Darco KB-G (0.5% w/w relative to substrate) before final recrystallization, achieving an APHA color below 50 and a clarity validated by EP 2.2.2 Degree of Opalescence as Reference Suspension II. This material is supplied in HDPE drums with double LDPE liners under inert atmosphere and is designated exclusively for Paritaprevir/Grazoprevir developer pipelines requiring full CE/EMA/FDA drug master file documentation. Published data for solid-state photostability of this specific intermediate under ICH Q1B conditions is limited; a precautionary storage at 2–8 °C protected from light is recommended based on forced degradation data showing a 0.3% total impurity increase after 48 hours of 365 nm irradiation at 25 °C.